Clinical Trial for Alpha-1 Antitrypsin Deficiency

Clinical Study of Fazisiran for Efficacy & Safety in People with Alpha-1 Antitrypsin Deficiency Associated Liver Disease

A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F2 to F4 Fibrosis

Eligibility Requirements:

  •  18 to 75 years of age, inclusive
  • Not have smoked any substance for the past 12 months
  • Have a confirmed or suspected diagnosis of the PiZZ genotype Alpha-1 Antitrypsin Deficiency or have a family member with a confirmed or suspected diagnosis
  • Not have hepatocellular carcinoma (HCC)

All study participants will receive the assigned investigational study treatment, study-related medical exams, and study-related laboratory tests at no cost. Reimbursement for travel expenses may be available. Further details about study support can be discussed with the study team.

Learn more about the Redwood Study for Alpha-1 Liver Disease by watching this informative video:

 

VISIT THE TRIAL SITE TO SEE IF YOU QUALIFY

The American Liver Foundation receives contributions and funding from clinical trial and study sponsors but does not evaluate or endorse any clinical trials or studies and is not affiliated with any of the sponsors

Return to Main Clinical Trials Page